PCI Biotech Holding

PCI Biotech (OSE:PCIB) is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities.

The company is applying PCI to two distinct paradigms:

- fimaVACC - Enhanced T-cell induction for therapeutic vaccination
- fimaNAC - Nucleic acid therapeutics delivery

Clinical proof-of-concept has been achieved in the lead programme fimaVacc, which applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines. The fimaNAc programme utilises the triggered endosomal release to provide effective intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics.

2007

Worldwide